https://www.selleckchem.com/products/abt-199.html
the final aim of adding new insight into the potential mechanisms by which curcumin exerts its effects. The clinical features of adult-onset atopic dermatitis (AD) are heterogeneous and the diagnosis can be a challenge. A new biologic drug (dupilumab) has been approved for moderate to severe AD in adult patients. The efficacy and safety have been demonstrated in clinical trials, but these studies do not reflect conditions in daily practice and do not consider the different clinical manifestations of AD. Analyzing the dupilumab activity
Curtir
Comentario
Compartilhar
